Partners Media Releases Contact Us


As a biomedical company dedicated to research and development of in vitro diagnostics for early cancer detection,
we will become the world's best company by contributing to the promotion of people's health and happiness.



Union for International Cancer Control (UICC)

  • 1. The largest and oldest global cancer Organization
    Founded in 1933, UICC is headquartered in Geneva, Switzerland. UICC has a network of over 1,100 members, such as major cancer societies, foundations, ministries of health, and research
    institutions on cancer, across 170 countries.
    UICC is the only international cancer organization that represents all cancer types and entire cancer spectrum.
  • 2. Close working relation with agencies of the United Nations
    UICC earned a worldwide reputation for its efforts to encourage governments to ensure that cancer control remains a priority
    alongside the World Health Organization (WHO) and the World Economic Forum (WEF).
    UICC has an official cooperative relation with WHO and consultative status at the Economic and Social Council (ECOSOC). UICC collaborates closely with other key UN agencies including the International Agency for Research on Cancer (IARC),
    United Nations Office for Drugs and Crime (UNODC), and International Atomic Energy Agency (IAEA).
  • 3. Globally influential leaders within UICC
    HRH Princess Dina Mired of Jordan is UICC's President, and its Board of Directors consists of highly influential figures from countries, such as the US, Oman, Sweden, Brazil, Malaysia, and South Africa.
  • 4. Annually hosting and participating in cancer-related international platforms
    UICC holds annual international cancer platforms, like the World Cancer Leaders' Summit and the World Cancer Congress. Along with partners and members, President of Mexico, President of Uruguay, Her Majesty Queen of Spain, Her Majesty Queen of Malaysia, HRH Princess of Oman, Ministers of Health, UN agencies representatives among many others have recently joined UICC-led convening events to raise awareness on cancer control. UICC takes part in the UN General Assembly and the WHO-led World Health Assembly every year.
  • 5. World Cancer Day
    Since 2008, World Cancer Day has been celebrated on every February 4. World Cancer Day was created under the leadership of UICC to support and organize global campaigns for cancer awareness and prevention. Recently, 55 landmarks illuminated in 37 cities, 947 activities in 127 countries, over 15,000 press articles in 154 countries, and 62 governments' direct engagement have been recorded.

Patron Partnership Agreement

  • 1. Signing of Patron partnership agreement, the highest partnership level within UICC
    UICC builds an extensive network of partners including major cancer societies, international organizations, foundations, and corporations for the elimination of cancer in all countries. UICC has more than 1,150 members and 58 partners across 173 countries, and only 10 of them are Patron partners. Patron partners work closely with UICC to lead the change in the practical implementation of cancer-related policies for timely and accurate cancer diagnosis and treatment and eventually create a long-lasting and positive impact on societal progress. Patron partners are entitled to special benefits, such as the development of exclusive cancer-related programs and the opportunity to give a speech on international platforms. Patron partners include globally famous pharmaceutical companies, like Pfizer and Roche, and its other partners involve Novartis, AMGEN, Merck, Johnson & Johnson, Bayer, and others.
  • 2. The world's first small and medium-sized enterprise to join UICC as its Patron partner
    Since Patron partners are given opportunities to exert more influence on the world, the hasty selection of any Patron partner may undermine UICC's worldwide reputation. For this reason, the selection process is neither simple nor easy. CUBEBIO joins UICC as a Patron partner after this particular selection process and is afforded an opportunity to be in the same league as international pharmaceutical corporations, like Pfizer and Roche, in the field of cancer diagnosis.
  • 3. The world's first partner to have signed Patron partnership and program agreements at the same time
    UICC keeps its close working relations with partners and develops diverse programs in order to generate substantive impacts in relation to cancer diagnosis and treatment around the world. Patron partners develop cancer-related programs with UICC and extend these programs' reach and impact by making use of UICC's vast network of partners and members. Major partners of UICC's programs are Pfizer and Roche. Not only are they internationally large companies, but they have also been UICC’s Patron partners for many years. It is an unprecedented case that a new Patron partner, like CUBEBIO, signs the partnership agreement and the program agreement at the same time.
  • 4. Opportunities to gain global visibility and influence through activities on international platforms
    CUBEBIO has attended the 2019 World Cancer Leaders' Summit in Kazakhstan as UICC's Patron partner. CUBEBIO will raise awareness on the necessity and importance of early cancer detection through self-diagnosis, which can ultimately protect people around the world from cancer. CUBEBIO will organize sessions for people's health improvement through self-diagnostic technology by inviting major cancer societies, royal foundations, ministries of health, corporations, UN agencies, and others. CUBEBIO will participate in the UN General Assembly and the WHO-led World Health Assembly and host conferences with UICC to raise awareness on the significant contribution self-diagnostic technology can make to reducing global cancer incidence and mortality rates. The status of CUBEBIO and South Korea will increase within and beyond international medical and scientific cancer communities.
Cancer Early Detection and Self-Diagnosis (Shaping the future of cancer care) is a program jointly developed by CUBEBIO and UICC. Early detection of cancer through self-diagnosis can lead to a significant decrease in cancer incidence and death rates worldwide. It plays an important role in achieving UICC’s main strategy: reducing the global cancer burden by effective cancer control. This holistic and comprehensive program will ultimately contribute to saving lives by having access to improved detection and diagnosis. A commissioned UICC research and report on cancer early detection and self-diagnosis will make the case and increase awareness on the important role played by diagnosis in cancer care, present global trends of present and future technologies, highlight good practices, and provide in-depth information on win-win strategies within the cancer diagnosis framework (The report will be launched at the 2020 World Cancer Congress in Oman). In cooperation with UICC, CUBEBIO can actively engage in international networking through UICC’s extensive networks, thereby generating substantive impacts by its cancer early detection and self-diagnostic technology and increasing its visibility. CUBEBIO and UICC will be able to widen and deepen the discussion around the international research on early cancer detection and self-diagnosis and the practical implementation of its results. CUBEBIO will support moving the needle in early cancer detection and self-diagnosis and thus build a new culture and era for cancer diagnosis in the future. CUBEBIO will be positioned as one of UICC’s leading partners for playing a significant and influential role within the cancer community.

《Standart-Biotest》 LLC (Russia)

《Standart-Biotest》 LLC is a Russian corporation conducting the production of medicinal supplies and the wholesale business of pharmaceutical products, medical machinery, devices, and equipment.Since 2017, the Ministry of Health of the Russian Federation has enacted a policy where Russian citizens mandatorily receive regular cancer checkups once every three years, and 《Standart-Biotest》 LLC has been established for the implementation of the policy.Accordingly, 《Standart-Biotest》 LLC is supported by the National Medical Research Radiological Center, the Federal State Budgetary Institution of the Ministry of Health of the Russian Federation, and the Ministry of Health of the Russian Federation. The company is leading the advancement in the field of cancer diagnosis in the Russian market for the implementation of the national health strategy.

National Medical Research Radiology Center (Russia)

The largest medical center in the field of oncology, radiology, and urology as the Federal State Budgetary Institution (FSBI) of the Ministry of Health of the Russian FederationConsisting of Hertsen Moscow Oncology Research Institute, Tsyb Medical Radiological Research Center, and Lopatkin Scientific Research Institute of Urology and Interventional Radiology.905 beds and over 3,300 medical professionals, including 615 scientific researchers, 400 medical doctors, and 980 nurses.Over 22,000 surgeries, over 100,000 outpatient consultations, and over 60% high-tech medical care every year.Partnerships with international organizations, such as the World Health Organization (WHO), the International Agency for Research on Cancer (IARC), the International Atomic Energy Agency (IAEA), the Organization of European Cancer Institutes (OECI), the European Organization for Research and Treatment of Cancer (EORTC), and the Union for International Cancer Control (UICC).Partnerships with international research centers, hospitals, and educational facilities, like the National Cancer Center (US), University of Hiroshima (Japan), Peking University (China) and University of Hamburg (Germany).

Asan Medical Center

The most popular hospital with over 60,000 visitors per day on average No. 1 hospital in performing highly sophisticated surgeries on 9 major cancers and other diseases The International Healthcare Center for international patients whose number has been continuously increasing from 6,182 (2010) to 11,911 (2013), 17,999 (2018) Possessing the highest number of beds in South Korea as a single hospital (2,705 beds in Seoul and 1,748 beds in other branches) Joint research and development with internationally prestigious research institutions, such as Dana-Farber Cancer Institute (US), University of Minnesota (US), Korea Institute of Science and Technology (South Korea), etc.


A subsidiary of BHflex Manufacturer of key parts for electronic equipment with smart technology, such as Flexible Printed Circuit Board (FPCB) and Surface Mount Technology (SMT) FPCB is a key part of small- and medium-sized electronic products, such as smartphones, tablets, laptops, wearable devices, and camera modules. It is also lighter, smaller in volume, and more pliable than Printed Circuit Board (PCB) SMT is a technology for attaching Surface Mounted Components (SMC) to electronic circuits that can be mounted directly on the surface of PCB. It is also essential for the production of various electronic products ranging from smart devices to robots, automobiles Supplying key parts to major global IT companies, including Apple, Samsung Electronics, LG Electronics, Sony, Huawei, Xiaomi, and others Established subsidiaries in China and Vietnam in 2006 and 2013, respectively, and constructed a new plant in 2008

Samsung Securities

Underwriting IPOs of various biomedical firms expected to be worth billions of dollars in 2020 Building a balanced business portfolio across the enterprise through diversification of revenue sources by strengthening business capabilities in the wholesale and IB sectors AA+ rating (stable outlook recorded by 3 rating agencies) Signed an MOU with Montreal-based institutional investor, Caisse de depot et placement du Quebec (CDPQ), in relation to infrastructure investment in 2019, thereby becoming the first domestic financial investment company to have partnered with a globally renowned pension fund